Entering text into the input field will update the search result below

Aeterna Zentaris to get US patent for potential hormone disorder therapy AEZS-150

Mar. 02, 2022 9:42 AM ETAeterna Zentaris Inc. (AEZS), AEZS:CABy: Ravikash, SA News Editor

Business woman signs a patent. Intellectual property protection concept. Patent attorney.

Irina Vodneva/iStock via Getty Images

  • Aeterna Zentaris (AEZS +7.7%) said its licensor, The University of Sheffield received a notice of allowance from the U.S. Patent and Trademark Office (USPTO).
  • The patent application No. 16/608,611, entitled, “Parathyroid Hormone Fusion Polypeptide” includes claims intended to cover the company’s

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.